Sanket U Shah, MD
Ophthalmology · Milpitas
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 29
- 7 carriers
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
29 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shah’s office at (714) 732-1417 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
29 of 29 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A139153 · Current
Licensed to practise in California · since 2015 · expires 2027-11-30 · Maharashtra University of Health Sciences, Seth G.S. Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$24,180
Medicare paid this office $24,180 for 57 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 41 | $5,425 | $132 |
| Short return visit (20+ min) | 17 | $1,600 | $73 |
| Imaging of retina | 27 | $1,049 | $34 |
| Photography of the retina | 13 | $548 | $37 |
Procedures Medicare counted
| Cataract surgery | 13 | More than 36% of doctors who do this |
Who their Medicare patients are
57 Original Medicare patients in 2024. Average age 71 · Women 58% · Also on Medicaid 49% · Health risk score 1.55. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 68% · Diabetes 49% · Chronic kidney disease 25%.
The office billed $80,800, Medicare allowed $32,490 and paid $24,180; for 203 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 57 | 203 | 71 | 1.55 | $80,800 | $24,180 |
| 2023 | 892 | 4,171 | 77 | 1.20 | $2,061,770 | $429,840 |
| 2022 | 1,014 | 6,069 | 76 | 1.27 | $2,576,485 | $529,012 |
| 2021 | 1,070 | 7,518 | 75 | 1.34 | $1,969,015 | $661,747 |
| 2020 | 822 | 5,372 | 75 | 1.48 | $1,336,121 | $428,949 |
| 2019 | 435 | 1,789 | 71 | 1.37 | $556,960 | $178,104 |
| 2018 | 264 | 567 | 71 | 1.71 | $359,996 | $67,732 |
| 2017 | 35 | 39 | 76 | 1.41 | $23,541 | $2,535 |
| 2016 | 73 | 126 | 74 | 1.72 | $119,890 | $13,120 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Injection, aflibercept, 1 mg | 28 | $147,812 | None |
| Short return visit (20+ min) | 679 | $62,578 | $66 |
| Injection of drug into eye | 154 | $48,276 | $94 |
| Imaging of retina | 713 | $45,273 | $34 |
| Compounded drug, not otherwise classified | 109 | $24,856 | None |
| Removal of membrane of retina | 12 | $12,707 | $977 |
| Return visit (30+ min) | 124 | $12,440 | $91 |
| New patient visit (45+ min) | 49 | $6,420 | $131 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 48 | $6,039 | $123 |
| Photography of the retina | 155 | $5,279 | $29 |
| Established patient complete exam of visual system | 47 | $5,040 | $99 |
| New patient visit (30+ min) | 61 | $4,796 | $79 |
| Unclassified drugs | 22 | $3,095 | None |
| Short return visit | 22 | $845 | $38 |
| Exam of visual field with extended testing | 18 | $779 | $41 |
| 2d ultrasound scan of eye tissue and structures | 13 | $565 | $43 |
2022: 18 services
| Injection, aflibercept, 1 mg | 17 | $90,200 | None |
| Short return visit (20+ min) | 726 | $83,004 | $67 |
| Injection of drug into eye | 205 | $70,586 | $92 |
| Imaging of retina | 758 | $58,941 | $34 |
| Return visit (30+ min) | 428 | $51,705 | $100 |
| Compounded drug, not otherwise classified | 179 | $43,829 | None |
| Removal of membrane of retina | 16 | $17,131 | $952 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 119 | $13,477 | $108 |
| New patient visit (45+ min) | 89 | $12,108 | $136 |
| Photography of the retina | 351 | $11,247 | $26 |
| Removal of eye fluid (vitreous) between lens and retina | 12 | $8,231 | $686 |
| Removal of recurring cataract in lens capsule using a laser | 13 | $4,508 | $301 |
| Destruction of leaking blood vessels of retina using laser | 11 | $3,894 | $300 |
| Injection, bevacizumab, 10 mg | 25 | $2,675 | None |
| 2d ultrasound scan of eye tissue and structures | 26 | $1,227 | $40 |
| New patient visit (30+ min) | 12 | $1,182 | $98 |
| Injection of drug or substance into membrane covering eyeball | 12 | $683 | $46 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $75 | None |
2021: 19 services
| Injection of drug into eye | 221 | $98,290 | $98 |
| Short return visit (20+ min) | 601 | $76,967 | $79 |
| Compounded drug, not otherwise classified | 205 | $66,864 | None |
| Return visit (30+ min) | 526 | $61,813 | $93 |
| Imaging of retina | 649 | $55,912 | $36 |
| Injection, aflibercept, 1 mg | 11 | $51,778 | None |
| Established patient complete exam of visual system | 417 | $45,866 | $98 |
| Photography of the retina | 680 | $35,355 | $34 |
| Removal of membrane of retina | 26 | $26,418 | $978 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 17 | $22,345 | $1,176 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 154 | $17,365 | $109 |
| New patient visit (45+ min) | 76 | $9,445 | $124 |
| Destruction of leaking blood vessels of retina using laser | 23 | $8,913 | $279 |
| Photocoagulation treatment to prevent detachment of retina | 14 | $6,654 | $475 |
| Established patient problem focused exam of visual system | 80 | $6,601 | $72 |
| Removal of recurring cataract in lens capsule using a laser | 11 | $3,653 | $304 |
| 2d ultrasound scan of eye tissue and structures | 66 | $3,373 | $43 |
| New patient visit (30+ min) | 14 | $1,195 | $85 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 28 | $44 | None |
2020: 15 services
| Return visit (30+ min) | 658 | $87,342 | $88 |
| Injection of drug into eye | 180 | $61,384 | $87 |
| Compounded drug, not otherwise classified | 176 | $49,497 | None |
| Imaging of retina | 554 | $37,911 | $35 |
| Established patient complete exam of visual system | 186 | $22,563 | $105 |
| Removal of membrane of retina | 19 | $22,047 | $1,002 |
| Photography of the retina | 321 | $16,992 | $40 |
| Established patient problem focused exam of visual system | 138 | $16,641 | $77 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 11 | $15,302 | $1,177 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 111 | $10,698 | $95 |
| New patient visit (45+ min) | 94 | $10,284 | $109 |
| Destruction of leaking blood vessels of retina using laser | 26 | $9,280 | $299 |
| 2d ultrasound scan of eye tissue and structures | 43 | $2,636 | $45 |
| Short return visit (20+ min) | 31 | $2,144 | $61 |
| Exam of visual field with extended testing | 11 | $581 | $53 |
2019: 14 services
| Established patient complete exam of visual system | 189 | $27,088 | $107 |
| Injection of drug into eye | 49 | $17,805 | $89 |
| Removal of membrane of retina | 16 | $17,302 | $1,018 |
| New patient visit (45+ min) | 163 | $17,168 | $105 |
| Imaging of retina | 325 | $16,284 | $35 |
| Return visit (30+ min) | 131 | $14,602 | $86 |
| Compounded drug, not otherwise classified | 47 | $13,337 | None |
| Destruction of leaking blood vessels of retina using laser | 12 | $5,793 | $305 |
| Established patient problem focused exam of visual system | 57 | $4,865 | $74 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 50 | $4,355 | $82 |
| Short return visit (20+ min) | 35 | $2,614 | $62 |
| 2d ultrasound scan of eye tissue and structures | 17 | $968 | $54 |
| New patient visit (30+ min) | 12 | $918 | $77 |
| Photography of the retina | 15 | $660 | $44 |
2018: 12 services
| New patient visit (45+ min) | 76 | $10,242 | $135 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 11 | $6,738 | $481 |
| Return visit (30+ min) | 48 | $5,395 | $91 |
| Established patient complete exam of visual system | 37 | $5,130 | $112 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 13 | $4,118 | $294 |
| Imaging of retina | 82 | $3,672 | $37 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 17 | $3,601 | $212 |
| Short return visit (20+ min) | 37 | $2,572 | $55 |
| Injection of drug into eye | 15 | $2,572 | $89 |
| Established patient problem focused exam of visual system | 28 | $2,181 | $68 |
| Compounded drug, not otherwise classified | 15 | $1,719 | None |
| Removal of eye fluid (vitreous) between lens and retina | 12 | $1,530 | $127 |
2017: 1 service
| Short return visit (20+ min) | 22 | $1,306 | $52 |
2016: 3 services
| Removal of membrane of retina with removal of internal limiting membrane of retina | 13 | $2,088 | $161 |
| Short return visit (20+ min) | 19 | $1,391 | $60 |
| Photography of the retina | 12 | $981 | $70 |
Medicaid work
$5,991 in 2024
Medicaid paid $5,991 for 122 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 101 | $4,026 |
| Short return visit (20+ min) | 21 | $1,965 |
| 2024 | 122 | 2 | 20 | $5,991 |
| 2023 | 207 | 2 | 22 | $5,152 |
| 2022 | 187 | 4 | 34 | $20,672 |
| 2021 | 1,490 | 9 | 53 | $173,633 |
| 2020 | 2,152 | 8 | 90 | $220,189 |
| 2019 | 1,198 | 7 | 44 | $123,821 |
| 2018 | 86 | 2 | 23 | $2,197 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 106 | $2,615 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 101 | $2,537 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 36 | $13,831 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 78 | $2,850 |
| Injection, bevacizumab, 10 mg | 32 | $2,708 |
| Short return visit (20+ min) | 41 | $1,282 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 342 | $110,054 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 423 | $16,055 |
| Compounded drug, not otherwise classified | 173 | $13,397 |
| Return visit (30+ min) | 179 | $11,664 |
| Injection, bevacizumab, 10 mg | 82 | $7,218 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 92 | $6,856 |
| Short return visit (20+ min) | 106 | $3,667 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 74 | $3,398 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 19 | $1,323 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 433 | $118,006 |
| Compounded drug, not otherwise classified | 431 | $32,157 |
| Return visit (30+ min) | 453 | $28,493 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 632 | $24,145 |
| New patient visit (45+ min) | 47 | $4,806 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 45 | $4,546 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 69 | $4,524 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 42 | $3,512 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 206 | $64,932 |
| New patient visit (45+ min) | 188 | $17,060 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 428 | $15,052 |
| Compounded drug, not otherwise classified | 143 | $11,200 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 114 | $8,237 |
| Return visit (30+ min) | 53 | $3,927 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 66 | $3,412 |
2018
| New patient visit (45+ min) | 49 | $1,572 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 37 | $625 |
Drugs they prescribed that Part D paid
$22,986
Pharmacies billed $22,986 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 312) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
217 generic and 95 brand-name prescriptions · $22,986 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 51 | $2,426 | $48 |
| Latanoprost | 56 | $754 | $13 |
| Ketorolac Tromethamine | 20 | $671 | $34 |
| Brimonidine | 44 | $582 | $13 |
| Dorzolamide-Timolol | 31 | $526 | $17 |
See all 8 drugs
| Prednisolone Acetate | 51 | $2,426 | $48 |
| Latanoprost | 56 | $754 | $13 |
| Ketorolac Tromethamine | 20 | $671 | $34 |
| Brimonidine | 44 | $582 | $13 |
| Dorzolamide-Timolol | 31 | $526 | $17 |
| Erythromycin | 30 | $396 | $13 |
| Ofloxacin | 13 | $197 | $15 |
| Timolol Maleate | 14 | $105 | $8 |
Year by year
| 2024 | 312 | 112 | 0% (0) | 30% | $22,986 |
| 2023 | 398 | 138 | 0% (0) | 40% | $30,270 |
| 2022 | 611 | 182 | 0% (0) | 47% | $51,406 |
| 2021 | 828 | 224 | 0% (0) | 56% | $63,161 |
| 2020 | 657 | 201 | 0% (0) | 53% | $45,436 |
| 2019 | 403 | 139 | None | 53% | $37,797 |
| 2018 | 375 | 120 | None | 55% | $31,974 |
| 2017 | 96 | 42 | 0% (0) | 48% | $9,299 |
| 2016 | 302 | 92 | None | 52% | $23,838 |
| 2015 | 167 | 52 | 0% (0) | 50% | $7,319 |
| 2014 | 198 | 55 | None | 65% | $14,681 |
| 2013 | 86 | 32 | 0% (0) | 57% | $4,415 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Lumigan | 13 | $4,121 | $317 |
| Prednisolone Acetate | 100 | $3,882 | $39 |
| Brimonidine Tartrate-Timolol | 13 | $1,960 | $151 |
| Ketorolac Tromethamine | 46 | $1,473 | $32 |
| Dorzolamide-Timolol | 47 | $1,300 | $28 |
| Ofloxacin | 44 | $555 | $13 |
| Brimonidine | 26 | $519 | $20 |
| Latanoprost | 24 | $278 | $12 |
2022: 9 drugs
| Prolensa | 25 | $9,072 | $363 |
| Prednisolone Acetate | 146 | $5,333 | $37 |
| Brimonidine | 55 | $4,736 | $86 |
| Difluprednate | 20 | $3,100 | $155 |
| Dorzolamide-Timolol | 82 | $2,604 | $32 |
| Ketorolac Tromethamine | 55 | $1,787 | $32 |
| Ofloxacin | 63 | $857 | $14 |
| Latanoprost | 46 | $682 | $15 |
| Dorzolamide | 13 | $329 | $25 |
2021: 11 drugs
| Prednisolone Acetate | 252 | $9,564 | $38 |
| Brimonidine | 70 | $9,234 | $132 |
| Combigan | 14 | $5,804 | $415 |
| Prolensa | 16 | $5,106 | $319 |
| Durezol | 23 | $4,982 | $217 |
| Dorzolamide-Timolol | 83 | $3,732 | $45 |
| Ketorolac Tromethamine | 59 | $2,440 | $41 |
| Simbrinza | 11 | $2,039 | $185 |
| Ofloxacin | 125 | $1,649 | $13 |
| Latanoprost | 65 | $1,104 | $17 |
| Erythromycin | 19 | $316 | $17 |
2020: 10 drugs
| Prednisolone Acetate | 204 | $8,011 | $39 |
| Durezol | 37 | $7,670 | $207 |
| Brimonidine | 53 | $4,699 | $89 |
| Combigan | 11 | $2,460 | $224 |
| Dorzolamide-Timolol | 67 | $2,456 | $37 |
| Ofloxacin | 104 | $1,258 | $12 |
| Ketorolac Tromethamine | 34 | $1,161 | $34 |
| Latanoprost | 52 | $769 | $15 |
| Erythromycin | 21 | $346 | $16 |
| Timolol Maleate | 12 | $157 | $13 |
2019: 8 drugs
| Prednisolone Acetate | 124 | $4,906 | $40 |
| Combigan | 19 | $3,999 | $210 |
| Durezol | 15 | $2,856 | $190 |
| Ofloxacin | 84 | $1,134 | $13 |
| Brimonidine | 25 | $767 | $31 |
| Dorzolamide-Timolol | 17 | $513 | $30 |
| Latanoprost | 29 | $502 | $17 |
| Erythromycin | 11 | $96 | $9 |
2018: 13 drugs
| Combigan | 24 | $3,989 | $166 |
| Prednisolone Acetate | 89 | $3,565 | $40 |
| Ilevro | 13 | $3,489 | $268 |
| Durezol | 11 | $3,463 | $315 |
| Timolol Maleate | 15 | $990 | $66 |
| Atropine Sulfate | 24 | $918 | $38 |
| Ofloxacin | 30 | $447 | $15 |
| Dorzolamide | 18 | $430 | $24 |
| Neomycin-Polymyxin-Dexameth | 25 | $387 | $15 |
| Dorzolamide-Timolol | 12 | $233 | $19 |
| Brimonidine | 21 | $188 | $9 |
| Latanoprost | 12 | $147 | $12 |
| Polymyxin B Sul-Trimethoprim | 17 | $138 | $8 |
2017: 2 drugs
| Prednisolone Acetate | 16 | $991 | $62 |
| Dorzolamide-Timolol | 28 | $620 | $22 |
2016: 10 drugs
| Travatan Z | 39 | $7,572 | $194 |
| Brimonidine | 44 | $3,260 | $74 |
| Lumigan | 19 | $2,322 | $122 |
| Combigan | 11 | $1,370 | $125 |
| Prednisolone Acetate | 26 | $1,245 | $48 |
| Atropine Sulfate | 15 | $901 | $60 |
| Dorzolamide-Timolol | 42 | $808 | $19 |
| Neomycin-Polymyxin-Dexameth | 15 | $233 | $16 |
| Latanoprost | 13 | $157 | $12 |
| Timolol Maleate | 17 | $133 | $8 |
2015: 7 drugs
| Lumigan | 12 | $1,897 | $158 |
| Brimonidine | 16 | $1,637 | $102 |
| Latanoprost | 31 | $390 | $13 |
| Dorzolamide-Timolol | 19 | $385 | $20 |
| Timolol Maleate | 15 | $368 | $25 |
| Prednisolone Acetate | 15 | $298 | $20 |
| Ketorolac Tromethamine | 11 | $162 | $15 |
2014: 7 drugs
| Lumigan | 45 | $4,129 | $92 |
| Brimonidine | 26 | $3,575 | $137 |
| Travoprost | 12 | $1,298 | $108 |
| Travatan Z | 11 | $1,210 | $110 |
| Prednisolone Acetate | 12 | $519 | $43 |
| Dorzolamide-Timolol | 24 | $452 | $19 |
| Latanoprost | 21 | $331 | $16 |
2013: 3 drugs
| Travatan Z | 12 | $1,328 | $111 |
| Lumigan | 14 | $989 | $71 |
| Prednisolone Acetate | 12 | $223 | $19 |
Money from drug and device companies
$321 in 2025
| 2025 | 3 | 4 | None | $321 |
| 2024 | 4 | 4 | $150 | $423 |
| 2022 | 7 | 11 | $500 | $967 |
| 2021 | 1 | 2 | None | $147 |
| 2020 | 2 | 3 | None | $155 |
| 2019 | 7 | 20 | None | $1,720 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bausch & Lomb Americas | Teneo | $262 | 2 payments
|
| Amgen | Tepezza | $31 | 1 payment
|
| ANI Pharmaceuticals | Yutiq | $28 | 1 payment
|
See all 4 published payments
| Amgen | Meals · 2025-05-05 | Tepezza | $31 |
| Bausch & Lomb Americas | Meals · 2025-04-25 | Miebo | $121 |
| Bausch & Lomb Americas | Meals · 2025-04-24 | Teneo | $141 |
| ANI Pharmaceuticals | Meals · 2025-03-19 | Yutiq | $28 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $423
| Cardinal Health 110 | None | $150 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $129 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Simplicity | $117 | 1 payment
|
| Amgen | Tepezza | $27 | 1 payment
|
2022: $967
| PTC Therapeutics | None | $500 | 1 payment
|
| Glaukos | Istent Inject W | $209 | 3 payments
|
| New World Medical | Kahook Dual Blade | $116 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $67 | 3 payments
|
| Sun Pharmaceutical Industries | Cequa | $33 | 1 payment
|
| BioTissue Holdings | Prokera | $24 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $18 | 1 payment
|
2021: $147
| Novartis Pharmaceuticals | Beovu | $147 | 2 payments
|
2020: $155
| Allergan | Ozurdex | $139 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Prolensa | $16 | 1 payment
|
2019: $1,720
| Novartis Pharmaceuticals | Beovu | $1,209 | 12 payments
|
| Bausch & Lomb a division of Bausch Health US | Lotemax | $206 | 2 payments
|
| Aerie Pharmaceuticals | Rhopressa | $125 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $124 | 1 payment
|
| Sun Pharmaceutical Industries | Bromsite | $21 | 1 payment
|
| Allergan | Combigan | $20 | 1 payment
|
| Alimera Sciences | Iluvien | $15 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Amgen Inc. · Abp 938 Global Phase 3 Study · 2021 | Their institution | $62,123 |
| Amgen Inc. · Abp 938 Global P3 Study · 2022 | Their institution | $364 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 89.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1528355799
- Licence
- CA A139153California A139153: Current · expires 2027-11-30
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1109 S Park Victoria Dr, Milpitas, CA, 95035
- NPI first listed
- 2011-07-07
- NPI last updated
- 2024-10-24
- NPI record certified
- 2024-10-24
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 46923 Warm Springs Blvd Ste 207, Fremont, CA, 94539
This office lists an electronic records connection.